LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 99-103

  Slater, Emily P ^a   Fendrich, Volker ^a   Strauch, Konstantin ^b,c   Rospleszcz, Susanne ^b,c   Ramaswamy, Annette ^a   Matthäi, Elvira ^a   Chaloupka, Brunhilde ^a   Gress, Thomas M ^a   Langer, Peter ^a   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3A; CONNECTIVE TISSUE GROWTH FACTOR; CXCL16 CHEMOKINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84875798461     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12373     Document Type: Article

References (23)

1. Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, et al. (2004). Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110, 902-906.
2. Hemminki K and Li X (2003). Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103, 525-530.
3. Brand RE, LerchMM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, and Canto MI (2007). Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469.
4. Bartsch DK, Gress TM, and Langer P (2012). Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 9, 445-453.
5. Hahn SA, Greenhalf W, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, et al. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95, 214-221.
6. Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, and Bartsch DK(2010). Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9, 335-343.
7. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, and Bartsch DK (2010). PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78, 490-494.
8. Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, et al. (2002). CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236, 730-737.
9. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, et al. (2008). A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5, e123.
10. Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, and Friess H (2008). Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 33, 297-308.
11. Märten A, Büchler MW, Werft W, Wente MN, Kirschfink M, and Schmidt J (2010). Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother 33, 219-224.
12. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, et al. (2008). Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 98, 1540-1547.
13. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, and Costello E (2009). Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 9, 567-576.
14. Gronborg M, Bunkenborg J, Kristiansen TZ, Jensen ON, Yeo CJ, Hruban RH, Maitra A, Goggins MG, and Pandey A (2004). Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3, 1042-1055.
15. Sipos B, Frank S, Gress T, Hahn S, and Klöppel G (2009). Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9, 45-54.
16. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, and DePinho RA (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20, 1218-1249.
17. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, JacobetzMA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
18. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, and Tuveson DA (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483.
19. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, and Bartsch DK (2010). The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59, 630-637.
20. Hanahan D (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122.
21. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, et al. (2006). Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66, 95-106.
22. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, et al. (2009). Five Years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58, 1410-1418.
23. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, et al. (2010). Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 120, 4065-4076.